| Index | — | P/E | — | EPS (ttm) | -0.58 | Insider Own | 13.85% | Shs Outstand | 147.20M | Perf Week | 0.26% |
| Market Cap | 559.36M | Forward P/E | — | EPS next Y | -0.72 | Insider Trans | 0.00% | Shs Float | 111.06M | Perf Month | -13.44% |
| Enterprise Value | 456.36M | PEG | — | EPS next Q | -0.16 | Short Float | 13.53% | Perf Quarter | -36.45% | ||
| Income | -77.00M | P/S | 69.92 | EPS this Y | — | Short Ratio | 5.57 | Perf Half Y | -16.11% | ||
| Sales | 8.00M | P/B | 3.88 | EPS next Y | — | ROA | -42.15% | Short Interest | 15.03M | Perf YTD | 26.25% |
| Book/sh | 0.98 | P/C | 5.33 | EPS next 5Y | — | ROE | -61.65% | 52W High | 6.60 -42.42% | Perf Year | 52.61% |
| Cash/sh | 0.71 | P/FCF | — | EPS past 3/5Y | — | ROIC | -56.99% | 52W Low | 2.10 80.95% | Perf 3Y | -17.03% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | -35.63% 5.92% | Gross Margin | 95.61% | Volatility | 7.86% 7.97% | Perf 5Y | -76.53% |
| Dividend TTM | — | EV/Sales | 57.04 | EPS Y/Y TTM | — | Oper. Margin | -1050.16% | ATR (14) | 0.30 | Perf 10Y | -82.95% |
| Dividend Ex-Date | — | Quick Ratio | 3.46 | Sales Y/Y TTM | -50.00% | Profit Margin | -921.50% | RSI (14) | 41.61 | Recom | 2.18 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.46 | EPS Q/Q | -15.38% | SMA20 | 2.87% | Beta | 0.94 | Target Price | 10.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 0.00% | SMA50 | -21.30% | Rel Volume | 0.56 | Prev Close | 3.97 |
| Employees | 71 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | -16.27% | Avg Volume | 2.91M | Price | 3.80 |
| IPO Date | Oct 06, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 6.25% 17.80% | Net Debt/EBITDA | — | Volume | 1,644,576 | Change | -4.28% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-28-26 | Reiterated | Craig-Hallum | $10 → $9.00 | |
| Sep-01-26 | Initiated | Canaccord | Buy | $10 |
| May-05-26 | Initiated | Guggenheim | Buy | $12 |
| May-05-26 | Reiterated | Piper Sandler | Overweight | $11 |
| Apr-29-26 | Reiterated | Wedbush | Outperform | $10 |
| Apr-16-26 | Initiated | Oppenheimer | Outperform | $10 |
| Jan-30-26 | Initiated | Craig-Hallum | $10 | |
| Dec-23-24 | Upgrade | HC Wainwright & Co. | Neutral → Buy | |
| Nov-19-24 | Upgrade | BTIG | Neutral → Buy | $8.00 |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy | $7.00 |
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8 | 8 | 19 | 31 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 2 | 3 | 18 | — | — | — | — | — | |
| Gross Profit | 8 | 6 | 16 | 13 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 24 | 22 | 22 | 31 | — | — | — | — | — | |
| Research and Development | 65 | 53 | 34 | 98 | — | — | — | — | — | |
| Other Operating Expense | 6 | 7 | 102 | -18 | — | — | — | — | — | |
| Operating Income | -86 | -76 | -142 | -97 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | 11 | 10 | 9 | — | — | — | — | — | |
| Net Income Before Taxes | -77 | -65 | -132 | -89 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -77 | -65 | -132 | -88 | — | — | — | — | — | |
| Net Income From Continuing Operations | -77 | -65 | -132 | -88 | — | — | — | — | — | |
| Net Income | -77 | -65 | -132 | -88 | — | — | — | — | — | |
| EPS (Recurring) | -0.58 | -0.53 | -1.71 | -1.27 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.58 | -0.53 | -1.71 | -1.27 | — | — | — | — | — | |
| EPS (Diluted) | -0.58 | -0.53 | -1.71 | -1.27 | — | — | — | — | — | |
| EBITDA | -76 | -64 | -52 | -115 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 67.93 | 46.28 | 10.05 | 2.37 | — | — | — | — | — | |
| Gross Margin | 100.00 | 75.00 | 84.21 | 41.94 | — | — | — | — | — | |
| Operating Margin | -1,075.00 | -950.00 | -747.37 | -312.90 | — | — | — | — | — | |
| Net Margin | -962.50 | -812.50 | -694.74 | -283.87 | — | — | — | — | — | |
| Shares Outstanding | 143 | 123 | 77 | 70 | — | — | — | — | — | |
| Market Capitalization | 543 | 370 | 191 | 74 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kolbeck Roland Wilhelm | Chief Scientific Officer | Aug 01 '26 | Option Exercise | 0.00 | 36,375 | 0 | 36,375 | Aug 04 |
| Molineaux Christopher P. | Director | Jun 05 '26 | Option Exercise | 0.00 | 11,580 | 0 | 69,536 | Jun 08 |
| MILANO VINCENT | Director | Jun 05 '26 | Option Exercise | 0.00 | 11,580 | 0 | 28,896 | Jun 08 |
| Humphries William D. | Director | Jun 05 '26 | Option Exercise | 0.00 | 11,580 | 0 | 45,105 | Jun 08 |
| Mehra Anand | Director | Jun 05 '26 | Option Exercise | 0.00 | 11,580 | 0 | 726,403 | Jun 08 |
| GOWEN MAXINE | Director | Jun 05 '26 | Option Exercise | 0.00 | 11,580 | 0 | 33,334 | Jun 08 |
| SCHIFF ANDREW N | Director | Jun 05 '26 | Option Exercise | 0.00 | 11,580 | 0 | 25,540 | Jun 08 |
| Hall Jesse Wayne | Chief Medical Officer | May 01 '26 | Option Exercise | 0.00 | 36,375 | 0 | 36,375 | May 05 |
| Leonard Braden Michael | 10% Owner | Apr 23 '26 | Sale | 4.53 | 300,000 | 1,359,000 | 13,950,000 | Apr 27 |
| Balthaser Kevin | Chief Financial Officer | Mar 01 '26 | Option Exercise | 0.00 | 2,375 | 0 | 188,130 | Mar 03 |
| Loerop James | Chief Business Officer | Feb 03 '26 | Option Exercise | 0.00 | 20,875 | 0 | 198,197 | Feb 05 |
| Walker Neal | CEO | Feb 03 '26 | Option Exercise | 0.00 | 63,475 | 0 | 1,562,497 | Feb 05 |
| Davis Hugh M. | President and COO | Feb 03 '26 | Option Exercise | 0.00 | 18,675 | 0 | 45,425 | Feb 05 |
| Balthaser Kevin | Chief Financial Officer | Feb 03 '26 | Option Exercise | 0.00 | 22,025 | 0 | 192,204 | Feb 05 |
| Loerop James | Chief Business Officer | Feb 01 '26 | Option Exercise | 0.00 | 33,500 | 0 | 188,008 | Feb 05 |